• Over the next 25years, there would be increased emphasis on
    harnessing host factor to prevent or control HIV infection. Current approaches focus on interfering with viral attachment or
    replication. Future efforts would seek to harness anti-viral factors and co-factors to stop or reduce HIV infection. This would provide a pipeline of novel targets for drug development with reduced possibility of resistance. But because HIV attacks innate factors in your body, there may be an increased risk of untoward effects and cellular toxicity with this approach.• HIV infection has been associated with premature aging. Efforts would be directed at investigating links between aging and HIV.
    HIV disease including its impact on premature aging in multiple body systems. Perhaps the HIV field can harness the global interest in prolonging youthfulness to revitalize the global HIV research infrastructure.

    • Efforts shall be directed at developing simple test to identify
    acute HIV infection. Probably half of all transmission occurs in
    the “window period” before people develop antibodies that show up on today’s rapid HIV tests. It should be possible to develop a test that has 3 windows: one that indicates no infection, acute infection and seroconvertion. Such a test would allow the world to identify pockets of high transmission and thereby help plan and target prevention efforts better, conduct routine surveillance of incidence rather than prevalence, and counsel people at high risk of transmitting virus to their sexual partners. This appears “doable” but needs to be prioritized.

    • There is increasing interest in the possibility of developing
    certain ARVs only for prevention. There are currently other
    efforts in disease prevention fields where certain drugs are
    reserved for prevention versus treatment eg in tuberculosis
    management This may possibly be explored for PreP when proven effective